1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited

202.25
INR
-1.45
(-0.71%)
8.48EPS
22.24P/E
6.79BMarket Cap
Kilitch Drugs (India) Limited
BSE:KILITCH
(Bombay Stock Exchange)

Recent

price

202.25

P/E

ratio

22.24

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
54.1
4.67
12.27
5.51
7.04
7.76
10.04
18.45
27.15
15.59
21.53
35.51
43.6
47.18
60.01
69.54
68.88
Revenue per Share
3.88
3.3
1.21
0.44
-0.11
-4.14
-3.29
1.9
1.28
0.27
1.16
2.32
3.28
4.49
8.12
8.91
8.73
Basic EPS, GAAP
-0.82
-1.27
0.55
-11.52
-2.82
6.37
0.41
0.53
-6.24
-1.92
2.96
-0.76
-0.39
-2.45
5.34
7.08
- -
Free Cash Flow per Basic Share
0.57
0.06
17.06
- -
0.01
0.03
0.01
0.02
0.32
0.57
- -
0.38
- -
- -
- -
- -
- -
Dividend per Share
31.18
42.36
44.02
44.46
44.33
39.84
37.42
39.92
38.58
37.49
40.15
43.68
47.6
53.64
61.56
79.99
- -
Book Value per Share
31.15
42.29
43.98
44.44
44.32
27.37
28.07
30.95
31.05
30.26
33.18
36.99
41.17
47.61
55.81
74.85
- -
Tangible Book Value per Share
27
231
27
27
27
27
27
27
30
32
32
32
32
33
33
34
34
Basic Weighted Avg Shares
1,463
1,080
332
149
190
210
272
499
814
491
681
1,130
1,389
1,536
1,972
2,353
2,372
Sales/Revenue/Turnover
11.27
7.18
-13.61
-33.84
-13.87
-61.24
-36.83
13.09
12.31
-3.03
5.51
8.64
10.33
13.73
14.52
14.51
13.66
Operating Margin (%)
56
49
12
14
19
100
98
20
21
20
20
25
36
33
31
36
39
Depreciation Expense
105
763
33
12
-3
-112
-89
52
38
8
37
74
104
146
267
302
301
Net Income, GAAP
20.04
21.62
- -
- -
- -
- -
- -
15.71
55.4
47.61
26.43
35.37
31.06
29.86
27.66
23.68
25.25
Effective Tax Rate (%)
7.17
70.68
9.89
7.9
-1.52
-53.33
-32.73
10.32
4.7
1.71
5.39
6.52
7.52
9.51
13.54
12.82
12.67
Profit Margin (%)
13
1,068
1,086
872
399
376
369
481
448
338
70
448
575
818
896
1,006
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
278
586
- -
LT Debt
859
1,156
1,191
1,202
1,199
1,077
1,012
1,128
1,232
1,205
1,295
1,403
1,506
1,757
2,005
2,769
- -
Total Equity
9.57
67.55
- -
- -
- -
- -
- -
2.88
2.24
-0.59
1.81
3.86
5.76
7.72
8.97
8.44
- -
Return on Invested Capital (%)
12.2
69.26
- -
- -
- -
- -
- -
4.78
3.25
0.92
2.98
6.1
9.6
10.41
14.05
11.4
- -
Return on Capital (%)
13.24
76.75
2.81
0.98
-0.24
-9.83
-8.51
4.83
3.29
0.7
2.99
5.53
7.19
8.91
14.1
12.52
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
301
- -
LT Borrowings
- -
586
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
6,133
4,459
6,786

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,222
- -
Cash, Cash Equivalents & STI
- -
687
- -
Accounts Receivable, Net
- -
1,202
- -
Inventories
- -
120
- -
Total Current Liabilities
- -
1,216
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
301
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.44%
16.91%
38.12%
Free Cash Flow
-171.26%
18.6%
36.57%
Net Income, GAAP
33.19%
55.62%
12.98%
Sales/Revenue/Turnover
32.24%
29.42%
19.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
335
475
562
612
1,972
2026
431
489
538
896
2,353
2027
449
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.41
2.68
1.85
3.16
8.12
2026
0.94
2.49
1.25
4.24
8.91
2027
0.83
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kilitch Drugs (India) Limited Kilitch Drugs (India) Limited, founded in 1978 and headquartered in Mumbai, Maharashtra, India, manufactures and markets a diverse portfolio of pharmaceutical formulations including sterile dosages such as injectables, ophthalmics, large volume parenterals, and nasal products; oral solid dosages encompassing tablets, capsules, dry syrups, and powders; effervescent tablets and granules like ROIPAR, DUREGRA, and ROIVIT; nutritional supplements including CELTINE and multi-vitamins; medical devices such as the CE-certified C-Seal topical skin adhesive; and cosmetics and herbal products featuring oils, creams, lotions, and pastes for skin, hair, personal care, and conditions like sore throat, prostate issues, diabetes, and obesity. The company operates manufacturing facilities in India, including sites in Patalganga, Maharashtra, and Khopoli for diabetes, weight-loss medicines, and biosimilars targeting US and EU approvals, as well as in Ethiopia producing cephalosporins in tablets, capsules, injectables, and dry powders; it exports to markets in the Middle East, Sudan, Yemen, South America, and Miami, serving therapeutic areas such as gastroenterology, anti-inflammatories, anti-malarials, anti-infectives, oncology, cardiovascular, anti-diabetics, and veterinary products with brands like Klavmox, Onecef, Tysabri, and Evermil. Subsidiaries include Monarchy Healthserve Private Limited and Kilitch Estro Biotech Plc, in which it agreed to acquire an additional 11.09% stake for INR 17.3 million in January 2025; recent developments encompass a rights issue launched in July 2025 opening July 23 and closing August 21 at INR 375 per share to raise approximately INR 50 crore for expansion, alongside revenue growth to INR 195.30 crore and profit after tax of INR 31.16 crore in FY2025, and investor Mukul Agrawal acquiring a 1.3% stake.